Lymphoma Clinical Trials

A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 173 clinical trials
None
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199) With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.

abt-199
bendamustine
acalabrutinib
obinutuzumab
rituximab
  • 361 views
  • 18 Nov, 2021
  • 251 locations
None
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

This study will explore 2 different doses of inotuzumab ozogamicin including the dose that is approved and a lower dose. The main purpose of this study is to evaluate whether a dose of inotuzumab ozogamicin, lower than the approved dose, could be recommended for adult patient with relapsed or refractory …

refractory acute lymphoblastic leukemia
lymphoma
kinase inhibitor
blast cells
lymphoblasts
  • 178 views
  • 29 Nov, 2021
  • 80 locations
None
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions. The study is divided …

cancer
anemia
vasectomy
bilateral oophorectomy
  • 23 views
  • 29 Nov, 2021
  • 161 locations
None
Durvalumab and Tremelimumab for Pediatric Malignancies

The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined

durvalumab
leukemia
lymphoma
acute leukemia
cancer
  • 15 views
  • 28 Nov, 2021
  • 27 locations
None
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

pembrolizumab
lung cancer
nivolumab
erlotinib
crizotinib
  • 1114 views
  • 28 Nov, 2021
  • 1140 locations
None
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got worse) after stopping treatment.

measurable disease
lymphoma
brentuximab
classical hodgkin lymphoma
t-cell lymphoma
  • 5 views
  • 29 Nov, 2021
  • 24 locations
None
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

Background Primary effusion lymphoma (PEL) is a rare disease with no standard treatment. Researchers want to see if a drug called lenalidomide along with common

filgrastim
vincristine
prednisone
rituximab
methotrexate
  • 9 views
  • 17 Nov, 2021
  • 1 location
None
Study of TG-1801 in Subjects With B-Cell Lymphoma

Phase 1 first in human Study to Assess the Bispecific Antibody TG-1801 in Subjects with B-Cell Lymphoma

b-cell lymphoma
measurable disease
filgrastim
refractory b-cell non-hodgkin lymphoma
neutrophil count
  • 20 views
  • 20 Nov, 2021
  • 5 locations
None
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma GRALE

Subjects have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease or severe chronic active Epstein Barr Virus (CAEBV) which has come back, is

white blood cells
biopsy tissue
investigational therapy
primary disease
hodgkin's disease
  • 73 views
  • 17 Nov, 2021
  • 2 locations
None
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.

b-cell lymphoma
measurable disease
lymphoma
bendamustine
tg-1501
  • 13 views
  • 26 Nov, 2021
  • 10 locations